资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.

J Immunother Cancer. 2019;

LiuSong，MatsuzakiJunko，WeiLei，TsujiTakemasa，BattagliaSebastiano，HuQiang，CortesEduardo，WongLaiping，YanLi，LongMark，MiliottoAnthony，BatemanNicholas W，LeleShashikant B，ChodonThinle，KoyaRichard C，YaoSong，ZhuQianqian，ConradsThomas P，WangJianmin，MaxwellGeorge L，LugadeAmit A，OdunsiK

Products/Services Used	Details	Operation
Peptide Synthesis	Synthetic peptides for neoepitopes and the corresponding wild-type epitopes were manufactured at > 90% purity (Genscript, Piscataway, NJ).	Get A Quote

摘要

Efficient identification of neoantigen-specific T-cell responses in epithelial ovarian cancer (EOC) remains a challenge. Existing investigations of spontaneous T-cell response to tumor neoepitope in EOC have taken the approach of comprehensive screening all neoantigen candidates， with a validation rate of 0.5-2%.